Kintor says China Phase III trial of KX-826 1.0% for male AGA met its primary endpoint

Reuters03-18

Kintor says China Phase III trial of KX-826 1.0% for male AGA met its primary endpoint

Kintor reported top-line results from the phase III stage of its pivotal phase II/III trial of KX-826 tincture 1.0% and 0.5% for male adult androgenetic alopecia in China, and said the phase III stage met its primary endpoint. In an analysis of 666 patients treated for 24 weeks, target area non-vellus hair counts increased by 15.33 hairs/cm2 from baseline in the 1.0% twice-daily group and by 4.68 hairs/cm2 in the placebo group. The 1.0% twice-daily group showed a 10.65 hairs/cm2 increase versus placebo (P<0.0001). Kintor said no drug-related serious adverse events were observed, and adverse-event incidence was similar across the 1.0% twice-daily, 0.5% twice-daily, and placebo groups. The company said it plans to communicate with regulators in China and initiate near-term submission of a new drug application for KX-826 1.0%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kintor Pharmaceutical Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260318-12057954), on March 18, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620256316?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 20:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620256316","market":"nz","top_or_hot":-1,"title":"Kintor says China Phase III trial of KX-826 1.0% for male AGA met its primary endpoint","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kintor says China Phase III trial of KX-826 1.0% for male AGA met its primary endpoint\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kintor reported top-line results from the phase III stage of its pivotal phase II/III trial of KX-826 tincture 1.0% and 0.5% for male adult androgenetic alopecia in China, and said the phase III stage met its primary endpoint. In an analysis of 666 patients treated for 24 weeks, target area non-vellus hair counts increased by 15.33 hairs/cm2 from baseline in the 1.0% twice-daily group and by 4.68 hairs/cm2 in the placebo group. The 1.0% twice-daily group showed a 10.65 hairs/cm2 increase versus placebo (P&lt;0.0001). Kintor said no drug-related serious adverse events were observed, and adverse-event incidence was similar across the 1.0% twice-daily, 0.5% twice-daily, and placebo groups. The company said it plans to communicate with regulators in China and initiate near-term submission of a new drug application for KX-826 1.0%.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/KNTPF\">Kintor Pharmaceutical</a> Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260318-12057954), on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kintor says China Phase III trial of KX-826 1.0% for male AGA met its primary endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKintor says China Phase III trial of KX-826 1.0% for male AGA met its primary endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-18 20:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kintor says China Phase III trial of KX-826 1.0% for male AGA met its primary endpoint\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kintor reported top-line results from the phase III stage of its pivotal phase II/III trial of KX-826 tincture 1.0% and 0.5% for male adult androgenetic alopecia in China, and said the phase III stage met its primary endpoint. In an analysis of 666 patients treated for 24 weeks, target area non-vellus hair counts increased by 15.33 hairs/cm2 from baseline in the 1.0% twice-daily group and by 4.68 hairs/cm2 in the placebo group. The 1.0% twice-daily group showed a 10.65 hairs/cm2 increase versus placebo (P&lt;0.0001). Kintor said no drug-related serious adverse events were observed, and adverse-event incidence was similar across the 1.0% twice-daily, 0.5% twice-daily, and placebo groups. The company said it plans to communicate with regulators in China and initiate near-term submission of a new drug application for KX-826 1.0%.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/KNTPF\">Kintor Pharmaceutical</a> Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260318-12057954), on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL6kHkdH:1","article_id":"2620256316","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620256316","pubTimestamp":1773838491,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kintor reported top-line results from the phase III stage of its pivotal phase II/III trial of KX-826 tincture 1.0% and 0.5% for male adult androgenetic alopecia in China, and said the phase III stage met its primary endpoint. In an analysis of 666 patients treated for 24 weeks, target area non-vellus hair counts increased by 15.33 hairs/cm2 from baseline in the 1.0% twice-daily group and by 4.68 hairs/cm2 in the placebo group. The 1.0% twice-daily group showed a 10.65 hairs/cm2 increase versus placebo . Kintor said no drug-related serious adverse events were observed, and adverse-event incidence was similar across the 1.0% twice-daily, 0.5% twice-daily, and placebo groups. The company said it plans to communicate with regulators in China and initiate near-term submission of a new drug application for KX-826 1.0%.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","BK1515":"抗疫概念","BK1161":"生物科技","09939":"开拓药业-B"},"translate_title":"开拓药业表示，KX-826 1.0%治疗男性AGA的中国III期试验达到了主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09939":0.9},"content_text":"Kintor says China Phase III trial of KX-826 1.0% for male AGA met its primary endpoint\n    \n\n        Kintor reported top-line results from the phase III stage of its pivotal phase II/III trial of KX-826 tincture 1.0% and 0.5% for male adult androgenetic alopecia in China, and said the phase III stage met its primary endpoint. In an analysis of 666 patients treated for 24 weeks, target area non-vellus hair counts increased by 15.33 hairs/cm2 from baseline in the 1.0% twice-daily group and by 4.68 hairs/cm2 in the placebo group. The 1.0% twice-daily group showed a 10.65 hairs/cm2 increase versus placebo (P<0.0001). Kintor said no drug-related serious adverse events were observed, and adverse-event incidence was similar across the 1.0% twice-daily, 0.5% twice-daily, and placebo groups. The company said it plans to communicate with regulators in China and initiate near-term submission of a new drug application for KX-826 1.0%.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kintor Pharmaceutical Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260318-12057954), on March 18, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620256316","isCrawlerRequest":true}